A-POXIDE
Clinical safety rating: caution
A-POXIDE is a synthetic benzimidazole derivative classified as a proton pump inhibitor (PPI). It is indicated for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, and Helicobacter pylori eradication in combination with antibiotics.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
| Metabolism | Extensively metabolized in the liver via CYP2C19 (major) and CYP3A4 (minor) to inactive metabolites. CYP2C19 polymorphisms significantly affect clearance. |
| Excretion | Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites. |
| Half-life | Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (CrCl < 50 mL/min). |
| Protein binding | 95% bound to albumin. |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water with accumulation in tissues (brain, liver, kidneys). |
| Bioavailability | Oral: 80-90%; Intramuscular: 95-100%; no data for other routes. |
| Onset of Action | Oral: 30-60 minutes; Intramuscular: 15-30 minutes; Intravenous: 2-5 minutes. |
| Duration of Action | Duration of therapeutic effect is 6-8 hours for oral, 4-6 hours for IM, and 2-4 hours for IV. Clinical duration may be extended with hepatic impairment or repeat dosing due to accumulation. |
| Molecular Weight | 286.3 |
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment required for mild-to-moderate renal impairment (CrCl >30 mL/min). For severe renal impairment (CrCl <30 mL/min), maximum dose 20 mg daily. |
| Liver impairment | Mild impairment: no adjustment. Moderate-to-severe (Child-Pugh B/C): maximum dose 20 mg daily. |
| Pediatric use | Approved for GERD in children ≥1 year (weight-based: 0.5-1 mg/kg once daily; maximum 20 mg). Safety in infants <1 year not established. |
| Geriatric use | No specific dose adjustment, but monitor renal function and for increased risk of Clostridium difficile infection and osteoporosis-related fractures. |
| 1st trimester | Contraindicated: teratogenic effects (neural tube defects, cardiovascular malformations) based on animal and human data. |
| 2nd trimester | Avoid: associated with fetal toxicity, including reduced fetal growth and neurodevelopmental impairment. |
| 3rd trimester | Avoid: risk of neonatal withdrawal syndrome and potential respiratory depression. |
Clinical note
Pregnancy category B (FDA). No adequate well-controlled studies in pregnant women; use only if clearly needed and benefit outweighs risk. Avoid use during the first trimester.
| Placental transfer | Extensive placental transfer; achieves fetal plasma concentrations 50-100% of maternal levels. |
| Breastfeeding | A-POXIDE is excreted into breast milk in significant amounts; breastfeeding is not recommended due to risk of infant sedation and withdrawal. |
■ FDA Black Box Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve use for patients with inadequate alternatives.
| Common Effects | Headache, Diarrhea, Abdominal pain, Nausea, Flatulence, Constipation, Dizziness |
| Serious Effects | Acute interstitial nephritis, severe hypomagnesemia (especially with >1 year use), Clostridium difficile-associated diarrhea, and increased risk of fundic gland polyps. |
Hypersensitivity to A-POXIDE or any excipientsAcute narrow-angle glaucomaSevere respiratory insufficiencyMyasthenia gravisConcomitant use with strong CYP3A4 inhibitorsPregnancy
| Precautions | Risk of dependence and withdrawal reactions; avoid abrupt discontinuation. May cause CNS depression and impair cognitive function. Use caution in hepatic impairment and geriatric patients. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Risk of major malformations (neural tube defects, cleft palate) increased by 2-3 fold. Second/third trimester: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome. Chronic use: Fetal hydantoin syndrome (craniofacial anomalies, growth deficiency, intellectual disability). |
| Fetal Monitoring | Monitor maternal phenytoin serum levels (target 10-20 mcg/mL total, 1-2 mcg/mL free in pregnancy). Periodic blood counts, liver and renal function. Fetal ultrasound for structural anomalies; newborn assessment for withdrawal and coagulopathy (vitamin K prophylaxis). |
| Fertility Effects | No significant impairment of fertility reported in either sex. Long-term use may alter sex hormone binding globulin (SHBG) levels but clinical significance is unclear. |
| Avoid grapefruit and grapefruit juice as they may increase drug levels. Avoid alcohol. Taking with food may delay absorption but does not affect total bioavailability. |
| Clinical Pearls | A-POXIDE is a potent benzodiazepine with rapid onset; use lowest effective dose to minimize tolerance. Monitor for respiratory depression, especially in elderly or those with COPD. Abrupt discontinuation may cause withdrawal seizures; taper gradually over weeks to months. Avoid concurrent use with other CNS depressants including alcohol. |
| Patient Advice | Do not consume alcohol while taking this medication. · May cause drowsiness or dizziness; avoid driving or operating heavy machinery until you know how it affects you. · Do not stop taking abruptly; follow your doctor's instructions for tapering the dose. · Inform your doctor if you have a history of substance abuse or respiratory conditions. · Store at room temperature away from moisture and heat. · Take exactly as prescribed; do not increase dose without consulting your doctor. |